Conversion from cyclosporin a to tacrolimus as a non-surgical alternative to reduce gingival enlargement: a preliminary case series

Background: Gingival enlargement (GE) is a frequent side effect that occurs in organ transplant recipients (OTR) after the administration of cyclosporin A (CsA). The availability of new drugs used to suppress graft rejection in OTR offers an opportunity to manage GE non-surgically. This preliminary...

Descripción completa

Detalles Bibliográficos
Autores: Hernández Vallejo, Gonzalo, Arriba De La Fuente, Lorenzo De, Frías López, María Cruz, Macorra García, José Carlos De La, De Vicente, Juan Carlos, Jiménez, Carlos, Andrés Belmonte, Amado, Moreno González, Enrique
Tipo de recurso: artículo
Fecha de publicación:2003
País:España
Institución:Universidad Complutense de Madrid (UCM)
Repositorio:Docta Complutense
Idioma:español
OAI Identifier:oai:docta.ucm.es:20.500.14352/60359
Acceso en línea:https://hdl.handle.net/20.500.14352/60359
Access Level:acceso abierto
Palabra clave:Cyclosporin A/adverse effects
Follow-up studies
Gingival hyperplasia/etiology
Gingival hperplasia/therapy
Organ transplantation/complications
Tacrolimus/therapeutic use.
Periodoncia
3213.13 Ortodoncia-Estomatología
id ES_4604cca4a49a693ebb2ee3c547f6e082
oai_identifier_str oai:docta.ucm.es:20.500.14352/60359
network_acronym_str ES
network_name_str España
repository_id_str
spelling Conversion from cyclosporin a to tacrolimus as a non-surgical alternative to reduce gingival enlargement: a preliminary case seriesHernández Vallejo, GonzaloArriba De La Fuente, Lorenzo DeFrías López, María CruzMacorra García, José Carlos De LaDe Vicente, Juan CarlosJiménez, CarlosAndrés Belmonte, AmadoMoreno González, EnriqueCyclosporin A/adverse effectsFollow-up studiesGingival hyperplasia/etiologyGingival hperplasia/therapyOrgan transplantation/complicationsTacrolimus/therapeutic use.Periodoncia3213.13 Ortodoncia-EstomatologíaBackground: Gingival enlargement (GE) is a frequent side effect that occurs in organ transplant recipients (OTR) after the administration of cyclosporin A (CsA). The availability of new drugs used to suppress graft rejection in OTR offers an opportunity to manage GE non-surgically. This preliminary case series aimed to analyze the effect of CsA withdrawal and its substitution by another immunosuppressant in OTR with sever GE. Methods: Four organ transplants recipients who had recieved a liver or renal allograft were recruited for this study. All OTR had developed clinically severe CsA-induced GE. GE scores were assessed for each patient at baseline and at weeks 2, 4, 8, 12, 16 and 54 followng conversion to tacrolimus. Scaling and root planing were initially performed and repeated monthly during the fisrt 6 months. Careful polishing of the teeth was carried out once every 2 weeks until month 6 and then monthly until month 12. Hygiene instructions and reinforcement to optimize oral hygiene were maintained throughout the study. Results: the four patients showed a rapid decrease in their gingival symptoms and in the size of the gingivae. This change was clinically evident 8 weeks after conversion to tacrolimus. One year later, all the patients experienced GE regression, although some anatomic irregularities persisted in the interdental papillaea of one of the patients. No adverse effects from tacrolimus were observed during the study except in one patient who presented headaches. Conclusion: It seems that CsA withdrawal and its conversion to tacrolimus in organ transplant recipients who develop severe gingival enlargement, together with an extensive plaque control program, provide an effective means to control/eliminate gingival hyperplasia, with minimal risk of graft dysfunction.Universidad Complutense de Madrid20032003-01-0120032003-01-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.14352/60359reponame:Docta Complutenseinstname:Universidad Complutense de Madrid (UCM)Españolspaopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:docta.ucm.es:20.500.14352/603592026-06-02T12:44:21Z
dc.title.none.fl_str_mv Conversion from cyclosporin a to tacrolimus as a non-surgical alternative to reduce gingival enlargement: a preliminary case series
title Conversion from cyclosporin a to tacrolimus as a non-surgical alternative to reduce gingival enlargement: a preliminary case series
spellingShingle Conversion from cyclosporin a to tacrolimus as a non-surgical alternative to reduce gingival enlargement: a preliminary case series
Hernández Vallejo, Gonzalo
Cyclosporin A/adverse effects
Follow-up studies
Gingival hyperplasia/etiology
Gingival hperplasia/therapy
Organ transplantation/complications
Tacrolimus/therapeutic use.
Periodoncia
3213.13 Ortodoncia-Estomatología
title_short Conversion from cyclosporin a to tacrolimus as a non-surgical alternative to reduce gingival enlargement: a preliminary case series
title_full Conversion from cyclosporin a to tacrolimus as a non-surgical alternative to reduce gingival enlargement: a preliminary case series
title_fullStr Conversion from cyclosporin a to tacrolimus as a non-surgical alternative to reduce gingival enlargement: a preliminary case series
title_full_unstemmed Conversion from cyclosporin a to tacrolimus as a non-surgical alternative to reduce gingival enlargement: a preliminary case series
title_sort Conversion from cyclosporin a to tacrolimus as a non-surgical alternative to reduce gingival enlargement: a preliminary case series
dc.creator.none.fl_str_mv Hernández Vallejo, Gonzalo
Arriba De La Fuente, Lorenzo De
Frías López, María Cruz
Macorra García, José Carlos De La
De Vicente, Juan Carlos
Jiménez, Carlos
Andrés Belmonte, Amado
Moreno González, Enrique
author Hernández Vallejo, Gonzalo
author_facet Hernández Vallejo, Gonzalo
Arriba De La Fuente, Lorenzo De
Frías López, María Cruz
Macorra García, José Carlos De La
De Vicente, Juan Carlos
Jiménez, Carlos
Andrés Belmonte, Amado
Moreno González, Enrique
author_role author
author2 Arriba De La Fuente, Lorenzo De
Frías López, María Cruz
Macorra García, José Carlos De La
De Vicente, Juan Carlos
Jiménez, Carlos
Andrés Belmonte, Amado
Moreno González, Enrique
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidad Complutense de Madrid
dc.subject.none.fl_str_mv Cyclosporin A/adverse effects
Follow-up studies
Gingival hyperplasia/etiology
Gingival hperplasia/therapy
Organ transplantation/complications
Tacrolimus/therapeutic use.
Periodoncia
3213.13 Ortodoncia-Estomatología
topic Cyclosporin A/adverse effects
Follow-up studies
Gingival hyperplasia/etiology
Gingival hperplasia/therapy
Organ transplantation/complications
Tacrolimus/therapeutic use.
Periodoncia
3213.13 Ortodoncia-Estomatología
description Background: Gingival enlargement (GE) is a frequent side effect that occurs in organ transplant recipients (OTR) after the administration of cyclosporin A (CsA). The availability of new drugs used to suppress graft rejection in OTR offers an opportunity to manage GE non-surgically. This preliminary case series aimed to analyze the effect of CsA withdrawal and its substitution by another immunosuppressant in OTR with sever GE. Methods: Four organ transplants recipients who had recieved a liver or renal allograft were recruited for this study. All OTR had developed clinically severe CsA-induced GE. GE scores were assessed for each patient at baseline and at weeks 2, 4, 8, 12, 16 and 54 followng conversion to tacrolimus. Scaling and root planing were initially performed and repeated monthly during the fisrt 6 months. Careful polishing of the teeth was carried out once every 2 weeks until month 6 and then monthly until month 12. Hygiene instructions and reinforcement to optimize oral hygiene were maintained throughout the study. Results: the four patients showed a rapid decrease in their gingival symptoms and in the size of the gingivae. This change was clinically evident 8 weeks after conversion to tacrolimus. One year later, all the patients experienced GE regression, although some anatomic irregularities persisted in the interdental papillaea of one of the patients. No adverse effects from tacrolimus were observed during the study except in one patient who presented headaches. Conclusion: It seems that CsA withdrawal and its conversion to tacrolimus in organ transplant recipients who develop severe gingival enlargement, together with an extensive plaque control program, provide an effective means to control/eliminate gingival hyperplasia, with minimal risk of graft dysfunction.
publishDate 2003
dc.date.none.fl_str_mv 2003
2003-01-01
2003
2003-01-01
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.14352/60359
url https://hdl.handle.net/20.500.14352/60359
dc.language.none.fl_str_mv Español
spa
language_invalid_str_mv Español
language spa
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Docta Complutense
instname:Universidad Complutense de Madrid (UCM)
instname_str Universidad Complutense de Madrid (UCM)
reponame_str Docta Complutense
collection Docta Complutense
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407200785465344
score 15.301603

Similares en LA Referencia